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PKD: new avenues  
of treatment
An explosion of research has taken place 
on the biology and therapeutics of poly-
cystic kidney disease (PKD). The most 
exciting discovery is that most gene muta-
tions in mice and humans that cause cystic 
disease code for proteins in the primary 
cilium. This finding has attracted many 
scientists who previously did not think of 
their work as being related to kidney dis-
ease. In a paper in this issue, Torres and 
Harris review the most recent advances 
in research on the biology of PKD. They 
discuss the proteins known to be involved 
in causing the disease and their interact-
ing partners. They also present the ongoing 
clinical trials on the therapeutic advances to 
treat PKD. A related research paper in this 
issue by Gattone et al. discusses the use of 
rapamycin in the treatment of PKD in mice 
and measures the role of the mammalian 
target of rapamycin (mTOR) in causing the 
disease. These are indeed exciting times for 
PKD research. See pages 149 and 178.
Paraoxonase 
polymorphisms in CKD
Hundreds of papers on paraoxonase-1 in a 
variety of important clinical situations have 
been published, despite the knowledge of 
its specific biochemical function. Paraoxo-
nase-1 was initially discovered as an esterase 
that hydrolyzes organophosphorus toxins. 
It was then proposed to be an antioxidant 
enzyme preventing lipid oxidation, but the 
evidence of this proposition is not com-
pelling at present. However, a number of 
studies have found that polymorphisms of 
the enzyme are linked to systemic oxida-
tive stress and cardiovascular events. Now, 
Ichikawa et al. present a study in which 
they genotyped seven single-nucleotide 
polymorphisms (SNPs) within the PON1 
gene and determined their association with 
chronic kidney disease (CKD) in 2968 indi-
viduals from the general Japanese popula-
tion. A missense SNP (rs662) with a G-to-A 
substitution leading to an amino acid sub-
stitution (G[Arg]/A[Gln]) was significantly 
associated with albuminuria and estimated 
glomerular filtration rate (eGFR), especially 
in women. The A/A genotype in women had 
the highest prevalence of albuminuria and 
the lowest values of adjusted eGFR. Remark-
ably, this association was not found in men. 
Importantly, when the authors measured 
serum PON1 activity, they found it to be 
lowest in subjects with the A/A genotype. 
The mechanism by which PON1 affects 
proteinuria and CKD will require further 
studies. See page 183. 
Ghrelin increases 
appetite in ESRD 
patients
Many patients with end-stage renal disease 
(ESRD) are malnourished, partly because 
of loss of appetite. Recent advances in the 
control of satiety have revealed that ghrelin, 
a hormone secreted by the stomach, acts 
on the hypothalamus to affect food intake. 
Ashby et al. studied the effect of ghrelin 
administration on 12 malnourished dialy-
sis patients for 1 week. The administration 
of ghrelin increased its concentration in 
the blood for 2 hours. Also, it immediately 
increased appetite and energy intake for 
the first meal after injection. Food diaries 
and observations of study meals revealed 
that this effect continued for 1 week when 
patients were given daily injections of ghre-
lin. Energy expenditure, measured with 
free-living pulse and motion monitors, 
was unchanged. This double-blind, cross-
over study shows that ghrelin produced a 
sustained increase in appetite and energy 
intake, indicating that ghrelin or drugs 
acting on its receptor could be excellent 
appetite enhancers for this difficult-to-treat 
population of patients. See page 199.
It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
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